Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 5, 2012, Pages 785-797

  Wang, Yong Wei ^a   Wang, Shuang Jia ^a   Zhou, Yi Nan ^a   Pan, Shang Ha ^a   Sun, Bei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Escin; Gemcitabine; Nuclear factor B; Pancreatic cancer

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; ESCIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVITY; GENE EXPRESSION; GENE PRODUCT; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CARCINOMA; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; ESCIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NF-KAPPA B; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862291483     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1152-z     Document Type: Article

References (38)

1. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70:3606-3617
2. Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499
3. Arlt A, Vorndamm J, Müerköster S, Yu H, Schmidt WE, Fölsch UR, Schäfer H (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62:910-916 (Pubitemid 34126972)
4. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, Schäfer H (2003) Role of NF-kappaB and Akt/PI3 K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death. Oncogene 22:3243-3251 (Pubitemid 36712936)
5. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP (2005) Predominant Bcl- XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65:2344-2352 (Pubitemid 40490145)
6. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM, Mohammad M (2009) Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69:5575-5583
7. Diaz-Rubio E (2004) New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9:282-294 (Pubitemid 38765090)
8. Duffy JP, Eibl G, Reber HA, Hines OJ (2003) Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2:12
9. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH (2006) Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res 66:10553-10559 (Pubitemid 44799778)
10. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM (2002) Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123:2052-2063 (Pubitemid 35408327)
11. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB (2010) Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol 77:818-827
12. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
13. Ji DB, Xu B, Liu JT, Ran FX, Cui JR (2011) β-escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog 50:945-960
14. Kim MP, Gallick GE (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14:1284-1285 (Pubitemid 351413904)
15. Kong R, Sun B, Jiang H, Pan S, Chen H, Wang S, Krissansen GW, Sun X (2010) Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 291:90-98
16. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853-3861 (Pubitemid 46762173)
17. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Yadav VR, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB (2010) γ-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res 70:8695-8705
18. Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Nishimura Y, Imamura M (1999) Role of Bcl-2 family proteins (Bax, Bcl-2) and (Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 35:1374-1380 (Pubitemid 29397439)
19. Lee MA, Park GS, Lee HJ, Jung JH, Kang JH, Hong YS, Lee KS, Kim DG, Kim SN (2005) Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 5:127
20. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R (2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101:2351-2362 (Pubitemid 39458693)
21. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH (2005) Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:6934-6942 (Pubitemid 41060733)
22. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM (2003) Mitogenic and antiapoptotic role of constitutive NF-κB/ Rel activity in pancreatic cancer. Int J Cancer 105:735-746 (Pubitemid 36706095)
23. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M (2011) Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15:817-828
24. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T (2010) NF-κB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 295:214-228
25. Ming ZJ, Hu Y, Qiu YH, Cao L, Zhang XG (2010) Synergistic effects of β-aescin and 5-Xuorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 17:575-580
26. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
27. Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, Schäfer H (2003) Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 104:469-476 (Pubitemid 36323918)
28. Neumann M, Naumann M (2007) Beyond IkappaBs: alternative regulation of NF-κB activity. FASEB J 21:2642-2654 (Pubitemid 47372732)
29. Patlolla JM, Raju J, Swamy MV, Rao CV (2006) β-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther 5:1459-1466 (Pubitemid 44070482)
30. Shen DY, Kang JH, Song W, Zhang WQ, Li WG, Zhao Y, Chen QX (2011) Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspase-dependent pathway. Phytother Res 25:1519-1526
31. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268 (Pubitemid 29125078)
32. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796-1803 (Pubitemid 30305074)
33. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G (2010) Identification of β-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 334:285-293
34. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Xue DB, Bai XW, Sun B (2010) Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293:99-108
35. Wang J, Ma Y, Jiang H, Zhu H, Liu L, Sun B, Pan S, Krissansen GW, Sun X (2011a) Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. J Hepatol 55:359-368
36. Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, Chen H, Jiang HC, Pan SH, Xue DB, Bai XW (2011b) Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappaB pathway. Cancer Chemother Pharmacol: Epub ahead of print
37. Xiao GM, Wei J (2005) EVects of β-Aescin on the expression of nuclear factor-kappaB and tumor necrosis factor-alpha after traumatic brain injury in rats. J Zhejiang Univ Sci B 6:28-32
38. Zhou XY, Fu FH, Li Z, Dong QJ, He J, Wang CH (2009) Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. Planta Med 75:1580-1585